Imunon, INC S-1 registration statements

Imunon, a clinical-stage biotechnology company, is registering shares for resale by existing investors following a private placement, while simultaneously grappling with severe financial challenges, including multiple Nasdaq delisting notices and substantial doubt about its ability to continue as a going concern.

Imunon, Inc. is proceeding with a public offering of common stock and warrants, aiming to raise capital for general corporate purposes, including clinical development.

Imunon, Inc. plans to raise capital through a public offering of up to 15,000,000 shares of common stock and accompanying warrants, aiming to generate approximately $12 million for general corporate purposes.

Imunon, a clinical-stage biotech, aims to raise capital through a public offering of common stock, pre-funded warrants, and common warrants.

Imunon, Inc. has filed an amendment to its Form S-1 registration statement to allow selling stockholders to resell up to 5,000,000 shares of common stock issuable upon the exercise of outstanding warrants.

Imunon, Inc. has filed a registration statement for the resale of up to 5,000,000 shares of its common stock, which are issuable upon the exercise of outstanding warrants held by selling stockholders.

Imunon is offering up to $24 million in common stock and warrants to fund general corporate purposes.

Imunon, Inc. is launching a public offering to sell shares of common stock and warrants, aiming to raise capital for general corporate purposes.